Clin2
NCT06864403Possibly a fitRecruiting

Mirikizumab for chronic pouch inflammation

PouchitisPouches, IleoanalPouch, Ileal

Treatments studied

Part of Digestive system clinical trials.

This trial tests if mirikizumab can help people with chronic inflammation of the pouch (a surgically created internal reservoir) that doesn't respond well to antibiotics or acts like Crohn's disease. It aims to see if the drug can reduce symptoms like urgency, pain, and bleeding.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 4
Enrollment
25 people
Ages
18 years to 80 years
Study type
Interventional

Who can take part

  • You are between 18 and 80 years old.
  • You have had surgery to remove your colon and create a pouch (IPAA) for ulcerative colitis.
  • You have ongoing pouch inflammation that either needs constant antibiotics to control or doesn't respond to them, or you have a fistula or stricture in the pouch area.
  • Your doctor is already considering starting you on mirikizumab for your pouch condition.
  • You have not taken mirikizumab before and do not have certain infections or severe liver or kidney problems.
  • You are not pregnant or breastfeeding, and if you could become pregnant, you use effective birth control.
  • You can access the internet for study data entry.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06916390Recruiting· Phase 4
Testing guselkumab with antibiotics for chronic pouchitis

This study tests whether adding a medication called guselkumab to antibiotics can help people with chronic or recurring pouchitis, a condition that causes inflammation in the J-pouch after ulcerative colitis surgery. Participants will take antibiotics for the first 4 weeks and guselkumab as an injection over the course of the trial.

Leuven, Vlaams-Brabant
NCT05509777Recruiting· Phase 3
Mirikizumab for children with active Crohn’s disease

This study tests mirikizumab to reduce inflammation and symptoms in children with Crohn’s disease that is currently active. It may help if your Crohn’s has not improved enough (or stopped working) with at least one other Crohn’s medicine.

Los Angeles, California
NCT07292012Recruiting· Phase 4
Mirikizumab to heal intestinal damage in Crohn's disease

This trial tests if mirikizumab can reduce deep inflammation in the intestine walls in people with active Crohn's disease. It may help heal damage that shows up on an MRI scan.

Brest
NCT07686757Enrolling by invitation· Phase 4
Study of mirikizumab for ulcerative colitis and Crohn's disease

This study tests a new medicine called mirikizumab for people with ulcerative colitis or Crohn's disease who have not responded well to other treatments. It aims to see if mirikizumab can help control symptoms and improve quality of life.

Sun City, Arizona
NCT07059130Not yet recruiting· Phase 4
Mirikizumab for older adults with Crohn's or colitis

This trial tests a medication called Mirikizumab for adults over 60 with moderate to severe Crohn's disease or ulcerative colitis. It aims to see if the drug is safe and effective for older adults with these conditions.

Lawrence, Massachusetts
NCT07782021Not yet recruiting· Phase 4
Mirikizumab with surgery for Crohn's perianal fistulas

This study tests a combination of a drug called mirikizumab and a surgical procedure (curettage and closure) for people with Crohn's disease who have an active perianal fistula. The goal is to see if this treatment helps heal the fistula better than standard care.

Louis, Missouri

Hear when a new Pouchitis trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.